Driven by the Launch and Uptake of Human Genome Sciences/GlaxoSmithKline's ... MarketWatch (press release) The continued uptake of the premium-priced B-cell modulator rituximab will help to drive SLE market growth. Rituximab will achieve sales of nearly $300 million for SLE in 2020 and its uptake will be driven primarily by its use for SLE manifestations ... |
